Life Sciences, Pharma & Healthcare

Lennard KeijzerGaby Smeenk + 15 other experts

The largest life sciences practice at a top-tier full-service firm in the Netherlands

.. with a practice that spans the entire spectrum of legal services relevant to the pharmaceutical and healthcare industry and to biotech companies.

We have strength and depth across this multifaceted sector, and advise on all relevant angles of legal life sciences work: ranging from M&A, financing transactions, IPOs (on Euronext Amsterdam, NASDAQ or other venues), corporate and governance, licensing transactions (often on a global scale), competition, regulatory and IP strategic advice through to litigation, compliance and investigations.

Our in-house capabilities give us a unique position from which to advise clients involved in life sciences matters which are by nature, often multidisciplinary. We are regularly retained for major transactions in the life sciences sector and our litigation department handles several of the largest healthcare and life sciences cases in the Netherlands, ranging from patent litigation to class actions pertaining to faulty medical devices and medicine.

Recent Matters

27 February 2026

De Brauw advises Committed Capital on the sale of FYEO to EuroEyes

FYEO is the largest refractive surgery provider, including laser eye surgery and lens implantation, in the Netherlands. EuroEyes is a leading international specialist in refractive surgery, with more than 30 years experience in laser eye and lens implantation treatments for sharp vision without glasses or contact lenses. By joining the EuroEyes global platform, FYEO will integrate its deep local Dutch market presence with EuroEyes internationally renowned ophthalmology offering. De Brauw acted for Committed Capital on the sale of FYEO to EuroEyes.
21 February 2025

Axcel acquires De Tandartsengroep from HC Partners through its portfolio company Oral Care to create Northern European dental group

De Brauw advises Axcel on the acquisition by its portfolio company Oral Care of Dutch dental care provider De Tandartsengroep from HC Partners. The acquisition will significantly expand Oral Care’s presence in the Netherlands and marks another step in its aspirations in becoming a leading dental care group in Northern Europe.
19 February 2025

Axcel acquires De Tandartsengroep from HC Partners through its portfolio company Oral Care to create Northern European dental group

De Brauw advises Axcel on the acquisition by its portfolio company Oral Care of Dutch dental care provider De Tandartsengroep from HC Partners. The acquisition will significantly expand Oral Care’s presence in the Netherlands and marks another step in its aspirations in becoming a leading dental care group in Northern Europe.
Phenster De Brauw7 Mrt 0203

BROAD SPECTRUM

We cover a broad spectrum of Life Sciences work for pharmaceutical companies, biotech firms and medical supply companies.

On behalf of our strong client base in the food and drink industry (including Unilever, PepsiCo, Danone, JDE and P&G), we have a leading role in developments relating to food claims and the actions taken by the European Food Safety Authority (EFSA).

We are the patent litigation firm of choice for many multinationals wishing to coordinate their patent strategy throughout Europe. Our Patent Law practice members combine their strong foundation in patent and procedural law with their extensive knowledge of the economics of, and the mechanisms, in this sector.

Learn More about our patents practice